Positive Allosteric Modulators Market Share

Report ID: 3979
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

On the basis of geographical analysis, the global positive allosteric modulators market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is likely to hold largest revenue share by 2037, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.

The positive allosteric modulators market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the higher health awareness amongst the population, along with easy access of quality healthcare in the developed nations, such as, the United States. Moreover, the higher investment in the R&D activities in the region is further expected to boost the market growth. As per the World Bank data, 2.734% of GDP of North America was spend for R&D activities in 2018.

Browse key industry insights with market data tables & charts from the report:

Positive Allosteric Modulators Market Size & Share | Forecast Report 2037

Frequently Asked Questions (FAQ)

Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

The increasing prevalence of Parkinsonâ€™s disease, schizophrenia, Alzheimerâ€™s disease, and other mental disorder will boost the market growth.

Asia Pacific industry is likely to hold largest revenue share by 2037, on account of increasing investment in development of healthcare sector in the region, along with growing health awareness amongst the population.

The major players in the market are Eli Lilly and Company, Novartis AG, Bayer AG, Sanofi-aventis Groupe, Abbott Laboratories, Johnson & Johnson Services, Inc., Merck & Co., Inc., Siemens Healthcare GmbH, and Pfizer Inc.